Skip to main content
SpringerLink
Log in

HCV NS3/4A Protease Inhibitors and the Road to Effective Direct-Acting Antiviral Therapies

  • Chapter
  • First Online:
Hepatitis C Virus II

Abstract

Hepatitis C virus (HCV) currently infects over 185 million individuals around the world. Its persistence causes infected individuals to enter a chronic phase where their condition can lead to several different outcomes of liver disease. HCV therapies are becoming highly efficient and well tolerated due to improved understanding of the HCV biology and to the discovery of antivirals targeting essential viral functions. The NS3 protein with its co-factor NS4A forms a serine protease (NS3/4A protease) that is indispensable for the maturation of HCV polyprotein. The NS3/4A protease was identified as a prime antiviral drug target. Its exploration led to the development of peptidomimetic inhibitors based on substrates and N-terminal products and to the rapid selection of drug candidates. Ciluprevir (BILN 2061) was the first NS3/4A protease inhibitors in clinical trials and it established the proof-of-concept in humans for a novel class of selective anti-HCV agents specifically designed to inhibit an essential viral enzyme. The inclusion of protease inhibitors with the standard of care therapy established the first major therapeutic advancement against HCV infection. In conjunction with other classes of anti-HCV agents, these inhibitors contributed to the revolution of all-oral interferon-free combination therapies. This chapter provides a historical perspective of the past 25 years in the validation of NS3/4A protease as an important drug target and in the rationale behind inhibitor design that led to the development of promising HCV antiviral drugs for the treatment of HCV infection.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • AASLD (2010) Abstracts of the American Association for the Study of Liver Diseases 61st annual meeting and postgraduate course. October 29–November 2, 2010. Boston, Massachusetts, USA. Hepatology 52(Suppl):320A–1291A

    Google Scholar 

  • Annicchiarico BE, Siciliano M, Avolio AW, Caracciolo G, Gasbarrini A, Agnes S, Castagneto M (2008) Treatment of chronic hepatitis C virus infection with pegylated interferon and ribavirin in cirrhotic patients awaiting liver transplantation. Transplant Proc 40(6):1918–1920. doi:10.1016/j.transproceed.2008.06.002

    Article  CAS  PubMed  Google Scholar 

  • Barbato G, Cicero DO, Nardi MC, Steinkuhler C, Cortese R, De Francesco R, Bazzo R (1999) The solution structure of the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein provides new insights into its activation and catalytic mechanism. J Mol Biol 289(2):371–384. doi:10.1006/jmbi.1999.2745

    Article  CAS  PubMed  Google Scholar 

  • Bartels DJ, Zhou Y, Zhang EZ, Marcial M, Byrn RA, Pfeiffer T, Tigges AM, Adiwijaya BS, Lin C, Kwong AD, Kieffer TL (2008) Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis 198(6):800–807. doi:10.1086/591141

    Article  CAS  PubMed  Google Scholar 

  • Beaulieu P, Llinas-Brunet M (2002) Therapies for hepatitis C infection: targeting the non-structural proteins of HCV. Anti-Infect Agents 1(2):14. doi:10.2174/1568012023354983

    Google Scholar 

  • Behrens SE, Tomei L, De Francesco R (1996) Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J 15(1):12–22

    CAS  PubMed  PubMed Central  Google Scholar 

  • Benhamou Y, Hinrichsen H, Sentjens RE, Reiser M, Manns MP, Forns X, Avendano C, et al. Safety, tolerability and antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C, genotype 1, with advanced liver fibrosis. Hepatology 36, abstract 304

    Google Scholar 

  • Benhamou Y (2002) Safety, tolerability and antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C, genotype 1, with advanced liver fibrosis. Hepatology 36(304A)

    Google Scholar 

  • Blight KJ, Kolykhalov AA, Rice CM (2000) Efficient initiation of HCV RNA replication in cell culture. Science 290(5498):1972–1974

    Article  CAS  PubMed  Google Scholar 

  • Brenndorfer ED, Karthe J, Frelin L, Cebula P, Erhardt A, Schulte am Esch J, Hengel H, Bartenschlager R, Sallberg M, Haussinger D, Bode JG (2009) Nonstructural 3/4A protease of hepatitis C virus activates epithelial growth factor-induced signal transduction by cleavage of the T-cell protein tyrosine phosphatase. Hepatology 49(6):1810–1820

    Article  PubMed  Google Scholar 

  • Bressanelli S, Tomei L, Roussel A, Incitti I, Vitale RL, Mathieu M, De Francesco R, Rey FA (1999) Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc Natl Acad Sci U S A 96(23):13034–13039

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chatel-Chaix L, Germain MA, Gotte M, Lamarre D (2012) Direct-acting and host-targeting HCV inhibitors: current and future directions. Curr Opin Virol 2(5):588–598. doi:10.1016/j.coviro.2012.08.002

    Article  CAS  PubMed  Google Scholar 

  • Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244(4902):359–362

    Article  CAS  PubMed  Google Scholar 

  • Chu M, Mierzwa R, He L, King A, Patel M, Pichardo J, Hart A, Butkiewicz N, Puar MS (1999) Isolation and structure of SCH 351633: a novel hepatitis C virus (HCV) NS3 protease inhibitor from the fungus Penicillium griseofulvum. Bioorg Med Chem Lett 9(14):1949–1952

    Article  CAS  PubMed  Google Scholar 

  • Cicero DO, Barbato G, Koch U, Ingallinella P, Bianchi E, Nardi MC, Steinkühler C, Cortese R, Matassa V, De Francesco R, Pessi A, Bazzo R (1999) Structural characterization of the interactions of optimized product inhibitors with the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein by NMR and modelling studies. J Mol Biol 289(2):385–396

    Article  CAS  PubMed  Google Scholar 

  • De Francesco R, Pessi A, Steinkuhler C (1999) Mechanisms of hepatitis C virus NS3 proteinase inhibitors. J Viral Hepat 6(Suppl 1):23–30

    Article  PubMed  Google Scholar 

  • De Francesco R, Tomei L, Altamura S, Summa V, Migliaccio G (2003) Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. Antiviral Res 58(1):1–16

    Article  PubMed  CAS  Google Scholar 

  • Dustin LB, Rice CM (2007) Flying under the radar: the immunobiology of hepatitis C. Annu Rev Immunol 25:71–99. doi:10.1146/annurev.immunol.25.022106.141602

    Article  CAS  PubMed  Google Scholar 

  • EASL EAftSotL- (2013) A special meeting review edition: Advances in the treatment of Hepatitis C virus infection from EASL 2013: The 48th Annual Meeting of the European Association for the Study of the LiverApril 24–28, 2013 * Amsterdam, The NetherlandsSpecial Reporting on:* Simeprevir Plus Peginterferon/Ribavirin Is Associated with a High SVR12 Rate in Treatment-Naive Patients with Genotype 1 Hepatitis C Virus Infection* Addition of Simeprevir to Peginterferon/Ribavirin Is Associated with Faster Resolution of Fatigue in Treatment-Naive Patients* Sofosbuvir Plus Ribavirin Demonstrates Significant Efficacy in Multiple HCV Genotype 2/3 Populations* Daclatasvir Plus Sofosbuvir with or without Ribavirin Yields 100% SVR24 Rate in Genotype 1 Patients Who Fail Telaprevir or Boceprevir* Addition of TG4040 Vaccine to Peginterferon/Ribavirin Increases Sustained Virologic Response Rate at 24 Weeks in Genotype 1 Hepatitis C InfectionPLUS Meeting Abstract Summaries With Expert Commentary by: Ira M. Jacobson, MDJoan Sanford I. Weill Medical College at Cornell UniversityNew York, New York. Gastroenterol Hepatol 9(6 Suppl 3):1–18

    Google Scholar 

  • Eckart MR, Selby M, Masiarz F, Lee C, Berger K, Crawford K, Kuo C, Kuo G, Houghton M, Choo QL (1993) The hepatitis C virus encodes a serine protease involved in processing of the putative nonstructural proteins from the viral polyprotein precursor. Biochem Biophys Res Commun 192(2):399–406. doi:10.1006/bbrc.1993.1429

    Article  CAS  PubMed  Google Scholar 

  • Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, Nyberg A, Box TD, Younes Z, Enayati P, Green S, Baruch Y, Bhandari BR, Caruntu FA, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervain J, Planas R, Moreno C, Hassanein T, Xie W, King M, Podsadecki T, Reddy KR, Study P-I, Study P-I (2014) ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 370(21):1983–1992. doi:10.1056/NEJMoa1402338

    Article  PubMed  CAS  Google Scholar 

  • Fischmann TO, Weber PC (2002) Peptidic inhibitors of the hepatitis C virus serine protease within non-structural protein 3. Curr Pharm Des 8(28):2533–2540

    Article  CAS  PubMed  Google Scholar 

  • Foy E, Li K, Wang C, Sumpter R Jr, Ikeda M, Lemon SM, Gale M Jr (2003) Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 300(5622):1145–1148. doi:10.1126/science.1082604

    Article  CAS  PubMed  Google Scholar 

  • Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347(13):975–982. doi:10.1056/NEJMoa020047

    Article  CAS  PubMed  Google Scholar 

  • Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, Marcellin P, Manns M, Nikitin I, Poordad F, Sherman M, Zeuzem S, Scott J, Gilles L, Lenz O, Peeters M, Sekar V, De Smedt G, Beumont-Mauviel M (2013) Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 58(6):1918–1929. doi:10.1002/hep.26641

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Germain MA, Chatel-Chaix L, Gagne B, Bonneil E, Thibault P, Pradezynski F, de Chassey B, Meyniel-Schicklin L, Lotteau V, Baril M, Lamarre D (2014) Elucidating novel hepatitis C virus-host interactions using combined mass spectrometry and functional genomics approaches. Mol Cell Proteomics: MCP 13(1):184–203. doi:10.1074/mcp.M113.030155

    Article  CAS  PubMed  Google Scholar 

  • Gorbalenya AE, Koonin EV (1993) Helicases: amino acid sequence comparisons and structure-function relationships. Curr Opin Struct Biol 3(3):419–429

    Article  CAS  Google Scholar 

  • Grakoui A, McCourt DW, Wychowski C, Feinstone SM, Rice CM (1993a) Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites. J Virol 67(5):2832–2843

    CAS  PubMed  PubMed Central  Google Scholar 

  • Grakoui A, McCourt DW, Wychowski C, Feinstone SM, Rice CM (1993b) A second hepatitis C virus-encoded proteinase. Proc Natl Acad Sci U S A 90(22):10583–10587

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hedstrom L (2002) Serine protease mechanism and specificity. Chem Rev 102(12):4501–4524

    Google Scholar 

  • Hezode C, Fontaine H, Dorival C, Zoulim F, Larrey D, Canva V, De Ledinghen V, Poynard T, Samuel D, Bourliere M, Alric L, Raabe JJ, Zarski JP, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, Chazouilleres O, Abergel A, Guyader D, Metivier S, Tran A, Di Martino V, Causse X, Dao T, Lucidarme D, Portal I, Cacoub P, Gournay J, Grando-Lemaire V, Hillon P, Attali P, Fontanges T, Rosa I, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, Bronowicki JP, Group CS (2014) Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 147(1):132–142 e134. doi:10.1053/j.gastro.2014.03.051

    Google Scholar 

  • Hinrichsen H, Benhamou Y, Reiser M, Sentjens R, Wedemeyer H, Calleja JL, Forns X, Erhardt A, Crönlein J, Chaves RL, Yong CL, Nehmiz G, Steinmann GG (2002) First report on the antiviral efficacy of BILN 2061, a novel oral serine protease inhibitor, in patients with chronic hepatitis C genotype 1. Hepatology 36, abstract 379

    Google Scholar 

  • Hinrichsen H, Benhamou Y, Wedemeyer H, Reiser M, Sentjens RE, Calleja JL, Forns X, Erhardt A, Crönlein J, Chaves RL, Yong CL, Nehmiz G, Steinmann GG (2004) Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 127(5):1347–1355

    Article  CAS  PubMed  Google Scholar 

  • Hirowatari Y, Hijikata M, Tanji Y, Nyunoya H, Mizushima H, Kimura K, Tanaka T, Kato N, Shimotohno K (1993) Two proteinase activities in HCV polypeptide expressed in insect cells using baculovirus vector. Arch Virol 133(3–4):349–356

    Article  CAS  PubMed  Google Scholar 

  • Hong Z, Beaudet-Miller M, Lanford RE, Guerra B, Wright-Minogue J, Skelton A, Baroudy BM, Reyes GR, Lau JY (1999) Generation of transmissible hepatitis C virions from a molecular clone in chimpanzees. Virology 256(1):36–44. doi:10.1006/viro.1999.9603

    Article  CAS  PubMed  Google Scholar 

  • Ingallinella P, Altamura S, Bianchi E, Taliani M, Ingenito R, Cortese R, De Francesco R, Steinkuhler C, Pessi A (1998) Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products. Biochemistry 37(25):8906–8914. doi:10.1021/bi980314n

    Article  CAS  PubMed  Google Scholar 

  • Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S, Team AS (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364(25):2405–2416. doi:10.1056/NEJMoa1012912

    Article  CAS  PubMed  Google Scholar 

  • Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, Moroz L, Craxi A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Scott J, Sinha R, Beumont-Mauviel M (2014) Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 384(9941):403–413. doi:10.1016/S0140-6736(14)60494-3

    Article  CAS  PubMed  Google Scholar 

  • Jankowsky E, Fairman-William M (2010) An introduction to RNA helicases: superfamilies, families, and major themes, vol 19. RSC Biomolecular Sciences, Cambridge

    Book  Google Scholar 

  • Kakiuchi N, Komoda Y, Komoda K, Takeshita N, Okada S, Tani T, Shimotohno K (1998) Non-peptide inhibitors of HCV serine proteinase. FEBS Lett 421(3):217–220

    Article  CAS  PubMed  Google Scholar 

  • Kang X, Chen X, He Y, Guo D, Guo L, Zhong J, Shu HB (2013) DDB1 is a cellular substrate of NS3/4A protease and required for hepatitis C virus replication. Virology 435(2):385–394. doi:10.1016/j.virol.2012.10.025

    Article  CAS  PubMed  Google Scholar 

  • Kim JL, Morgenstern KA, Lin C, Fox T, Dwyer MD, Landro JA, Chambers SP, Markland W, Lepre CA, O’Malley ET, Harbeson SL, Rice CM, Murcko MA, Caron PR, Thomson JA (1996) Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87(2):343–355

    Article  CAS  PubMed  Google Scholar 

  • Kim JL, Morgenstern KA, Griffith JP, Dwyer MD, Thomson JA, Murcko MA, Lin C, Caron PR (1998) Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding. Structure 6(1):89–100

    Article  CAS  PubMed  Google Scholar 

  • Klibanov OM, Gale SE, Santevecchi B (2015) Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection. Ann Pharmacother 49(5):566–581. doi:10.1177/1060028015570729

    Article  CAS  PubMed  Google Scholar 

  • Kneteman NM, Weiner AJ, O’Connell J, Collett M, Gao T, Aukerman L, Kovelsky R, Ni ZJ, Zhu Q, Hashash A, Kline J, Hsi B, Schiller D, Douglas D, Tyrrell DL, Mercer DF (2006) Anti-HCV therapies in chimeric scid-Alb/uPA mice parallel outcomes in human clinical application. Hepatology 43(6):1346–1353. doi:10.1002/hep.21209

    Article  CAS  PubMed  Google Scholar 

  • Kohli A, Zayani S, Marti M, Nelson A, Osinusi A, Bon D, Hermann E, Kotb C, Silk R, Teferi G, Symonds W, Pand P, McHutchison JG, Subramanian M, Polis M, Masur H, Kottilil S (2012) Combination oral, ribavirin free, antiviral therapy to optimize treatment outcomes for hepatitis C treatment naïve patients: interim results from the NIAID SYNERGY Trial (6 & 12 weeks therapy). In: 64rd annual meeting of the American Association for the Study of Liver Diseases, Washington, DC

    Google Scholar 

  • Kolykhalov AA, Agapov EV, Blight KJ, Mihalik K, Feinstone SM, Rice CM (1997) Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 277(5325):570–574

    Article  CAS  PubMed  Google Scholar 

  • Kolykhalov AA, Mihalik K, Feinstone SM, Rice CM (2000) Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo. J Virol 74(4):2046–2051

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, Bernstein DE, Afdhal N, Vierling JM, Gordon SC, Anderson JK, Hyland RH, Dvory-Sobol H, An D, Hindes RG, Albanis E, Symonds WT, Berrey MM, Nelson DR, Jacobson IM (2013) Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 381(9883):2100–2107. doi:10.1016/S0140-6736(13)60247-0

    Article  CAS  PubMed  Google Scholar 

  • Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, Bos M, Cameron DR, Cartier M, Cordingley MG, Faucher AM, Goudreau N, Kawai SH, Kukolj G, Lagace L, LaPlante SR, Narjes H, Poupart MA, Rancourt J, Sentjens RE, St George R, Simoneau B, Steinmann G, Thibeault D, Tsantrizos YS, Weldon SM, Yong CL, Llinas-Brunet M (2003) An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426(6963):186–189. doi:10.1038/nature02099

    Article  CAS  PubMed  Google Scholar 

  • Landro JA, Raybuck SA, Luong YP, O’Malley ET, Harbeson SL, Morgenstern KA, Rao G, Livingston DJ (1997) Mechanistic role of an NS4A peptide cofactor with the truncated NS3 protease of hepatitis C virus: elucidation of the NS4A stimulatory effect via kinetic analysis and inhibitor mapping. Biochemistry 36(31):9340–9348. doi:10.1021/bi963054n

    Article  CAS  PubMed  Google Scholar 

  • LaPlante SR, Cameron DR, Aubry N, Lefebvre S, Kukolj G, Maurice R, Thibeault D, Lamarre D, Llinas-Brunet M (1999) Solution structure of substrate-based ligands when bound to hepatitis C virus NS3 protease domain. J Biol Chem 274(26):18618–18624

    Article  CAS  PubMed  Google Scholar 

  • LaPlante SR, Aubry N, Bonneau PR, Kukolj G, Lamarre D, Lefebvre S, Li H, Llinas-Brunet M, Plouffe C, Cameron DR (2000) NMR line-broadening and transferred NOESY as a medicinal chemistry tool for studying inhibitors of the hepatitis C virus NS3 protease domain. Bioorg Med Chem Lett 10(20):2271–2274

    Article  CAS  PubMed  Google Scholar 

  • LaPlante SR, Nar H, Lemke CT, Jakalian A, Aubry N, Kawai SH (2014) Ligand bioactive conformation plays a critical role in the design of drugs that target the hepatitis C virus NS3 protease. J Med Chem 57(5):1777–1789. doi:10.1021/jm401338c

    Article  CAS  PubMed  Google Scholar 

  • Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, Symonds WT, McHutchison JG, Membreno FE (2014a) Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 383(9916):515–523. doi:10.1016/S0140-6736(13)62121-2

    Article  CAS  PubMed  Google Scholar 

  • Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, DeJesus E, Pearlman B, Rabinovitz M, Gitlin N, Lim JK, Pockros PJ, Scott JD, Fevery B, Lambrecht T, Ouwerkerk-Mahadevan S, Callewaert K, Symonds WT, Picchio G, Lindsay KL, Beumont M, Jacobson IM (2014b) Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 384(9956):1756–1765. doi:10.1016/S0140-6736(14)61036-9

    Article  CAS  PubMed  Google Scholar 

  • Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Guyader D, Alric L, Bronowicki JP, Lester L, Sievert W, Ghalib R, Balart L, Sund F, Lagging M, Dutko F, Shaughnessy M, Hwang P, Howe AY, Wahl J, Robertson M, Barr E, Haber B (2015) Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 385(9973):1075–1086. doi:10.1016/S0140-6736(14)61795-5

    Article  CAS  PubMed  Google Scholar 

  • Lenz O, Verbinnen T, Lin TI, Vijgen L, Cummings MD, Lindberg J, Berke JM, Dehertogh P, Fransen E, Scholliers A, Vermeiren K, Ivens T, Raboisson P, Edlund M, Storm S, Vrang L, de Kock H, Fanning GC, Simmen KA (2010) In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 54(5):1878–1887. doi:10.1128/AAC.01452-09

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lenz O, Vijgen L, Berke JM, Cummings MD, Fevery B, Peeters M, De Smedt G, Moreno C, Picchio G (2013) Virologic response and characterisation of HCV genotype 2–6 in patients receiving TMC435 monotherapy (study TMC435-C202). J Hepatol 58(3):445–451. doi:10.1016/j.jhep.2012.10.028

    Article  CAS  PubMed  Google Scholar 

  • Li K, Foy E, Ferreon JC, Nakamura M, Ferreon AC, Ikeda M, Ray SC, Gale M Jr, Lemon SM (2005) Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A 102(8):2992–2997. doi:10.1073/pnas.0408824102

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Llinas-Brunet M, Bailey M, Deziel R, Fazal G, Gorys V, Goulet S, Halmos T, Maurice R, Poirier M, Poupart MA, Rancourt J, Thibeault D, Wernic D, Lamarre D (1998a) Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease. Bioorg Med Chem Lett 8(19):2719–2724

    Article  CAS  PubMed  Google Scholar 

  • Llinas-Brunet M, Bailey M, Fazal G, Goulet S, Halmos T, Laplante S, Maurice R, Poirier M, Poupart MA, Thibeault D, Wernic D, Lamarre D (1998b) Peptide-based inhibitors of the hepatitis C virus serine protease. Bioorg Med Chem Lett 8(13):1713–1718

    Article  CAS  PubMed  Google Scholar 

  • Llinas-Brunet M, Bailey M, Fazal G, Ghiro E, Gorys V, Goulet S, Halmos T, Maurice R, Poirier M, Poupart MA, Rancourt J, Thibeault D, Wernic D, Lamarre D (2000) Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors. Bioorg Med Chem Lett 10(20):2267–2270

    Article  CAS  PubMed  Google Scholar 

  • Llinas-Brunet M, Bailey MD, Bolger G, Brochu C, Faucher AM, Ferland JM, Garneau M, Ghiro E, Gorys V, Grand-Maitre C, Halmos T, Lapeyre-Paquette N, Liard F, Poirier M, Rheaume M, Tsantrizos YS, Lamarre D (2004) Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061. J Med Chem 47(7):1605–1608. doi:10.1021/jm0342414

    Article  CAS  PubMed  Google Scholar 

  • Lohmann V, Korner F, Herian U, Bartenschlager R (1997) Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity. J Virol 71(11):8416–8428

    CAS  PubMed  PubMed Central  Google Scholar 

  • Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R (1999) Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285(5424):110–113

    Article  CAS  PubMed  Google Scholar 

  • Lohmann V, Korner F, Dobierzewska A, Bartenschlager R (2001) Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J Virol 75(3):1437–1449. doi:10.1128/JVI.75.3.1437-1449.2001

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lok AS, Gardiner DF, Hezode C, Lawitz EJ, Bourliere M, Everson GT, Marcellin P, Rodriguez-Torres M, Pol S, Serfaty L, Eley T, Huang SP, Li J, Wind-Rotolo M, Yu F, McPhee F, Grasela DM, Pasquinelli C (2014) Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol 60(3):490–499. doi:10.1016/j.jhep.2013.10.019

    Article  CAS  PubMed  Google Scholar 

  • Love RA, Parge HE, Wickersham JA, Hostomsky Z, Habuka N, Moomaw EW, Adachi T, Hostomska Z (1996) The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 87(2):331–342

    Article  CAS  PubMed  Google Scholar 

  • Madala PK, Tyndall JD, Nall T, Fairlie DP (2010) Update 1 of: proteases universally recognize beta strands in their active sites. Chem Rev 110(6):PR1–PR31. doi:10.1021/cr900368a

    Article  CAS  PubMed  Google Scholar 

  • Manns MP, von Hahn T (2013) Novel therapies for hepatitis C – one pill fits all? Nat Rev Drug Discov 12(8):595–610. doi:10.1038/nrd4050

    Article  CAS  PubMed  Google Scholar 

  • Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358(9286):958–965

    Article  CAS  PubMed  Google Scholar 

  • Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, Janczewska E, Villamil F, Scott J, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M (2014a) Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 384(9941):414–426. doi:10.1016/S0140-6736(14)60538-9

    Article  CAS  PubMed  Google Scholar 

  • Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng CY, Chang TT, Everson GT, Heo J, Gerken G, Yoffe B, Towner WJ, Bourliere M, Metivier S, Chu CJ, Sievert W, Bronowicki JP, Thabut D, Lee YJ, Kao JH, McPhee F, Kopit J, Mendez P, Linaberry M, Hughes E, Noviello S, Team H-DS (2014b) All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 384(9954):1597–1605. doi:10.1016/S0140-6736(14)61059-X

    Article  CAS  PubMed  Google Scholar 

  • McHutchison JG, Patel K, Pockros P, Nyberg L, Pianko S, Yu RZ, Dorr FA, Kwoh TJ (2006) A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients. J Hepatol 44(1):88–96. doi:10.1016/j.jhep.2005.09.009

    Article  CAS  PubMed  Google Scholar 

  • Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A, Addison WR, Fischer KP, Churchill TA, Lakey JR, Tyrrell DL, Kneteman NM (2001) Hepatitis C virus replication in mice with chimeric human livers. Nat Med 7(8):927–933. doi:10.1038/90968

    Article  CAS  PubMed  Google Scholar 

  • Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E (2015) Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61(1):77–87. doi:10.1002/hep.27259

    Article  PubMed  Google Scholar 

  • Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, Tschopp J (2005) Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437(7062):1167–1172. doi:10.1038/nature04193

    Article  CAS  PubMed  Google Scholar 

  • Miller RH, Purcell RH (1990) Hepatitis C virus shares amino acid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus supergroups. Proc Natl Acad Sci U S A 87(6):2057–2061

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mizokami M, Yokosuka O, Takehara T, Sakamoto N, Korenaga M, Mochizuki H, Nakane K, Enomoto H, Ikeda F, Yanase M, Toyoda H, Genda T, Umemura T, Yatsuhashi H, Ide T, Toda N, Nirei K, Ueno Y, Nishigaki Y, Betular J, Gao B, Ishizaki A, Omote M, Mo H, Garrison K, Pang PS, Knox SJ, Symonds WT, McHutchison JG, Izumi N, Omata M (2015) Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis 15(6):645–653. doi:10.1016/S1473-3099(15)70099-X

    Article  CAS  PubMed  Google Scholar 

  • Morikawa K, Gouttenoire J, Hernandez C, Dao Thi VL, Tran HT, Lange CM, Dill MT, Heim MH, Donze O, Penin F, Quadroni M, Moradpour D (2014) Quantitative proteomics identifies the membrane-associated peroxidase GPx8 as a cellular substrate of the hepatitis C virus NS3-4A protease. Hepatology 59(2):423–433. doi:10.1002/hep.26671

    Article  CAS  PubMed  Google Scholar 

  • Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, Freilich BF, Younes ZH, Harlan W, Ghalib R, Oguchi G, Thuluvath PJ, Ortiz-Lasanta G, Rabinovitz M, Bernstein D, Bennett M, Hawkins T, Ravendhran N, Sheikh AM, Varunok P, Kowdley KV, Hennicken D, McPhee F, Rana K, Hughes EA, Team A-S (2015) All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 61(4):1127–1135. doi:10.1002/hep.27726

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Palanisamy N, Danielsson A, Kokkula C, Yin H, Bondeson K, Wesslen L, Duberg AS, Lennerstrand J (2013) Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a. Antiviral Res 99(1):12–17. doi:10.1016/j.antiviral.2013.04.018

    Article  CAS  PubMed  Google Scholar 

  • Pause A, Kukolj G, Bailey M, Brault M, Do F, Halmos T, Lagace L, Maurice R, Marquis M, McKercher G, Pellerin C, Pilote L, Thibeault D, Lamarre D (2003) An NS3 serine protease inhibitor abrogates replication of subgenomic hepatitis C virus RNA. J Biol Chem 278(22):20374–20380. doi:10.1074/jbc.M210785200

    Article  CAS  PubMed  Google Scholar 

  • Pol S, Corouge M (2014) Treatment of hepatitis C: perspectives. Med Mal Infect 44(10):449–454. doi:10.1016/j.medmal.2014.07.015

    Article  CAS  PubMed  Google Scholar 

  • Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP, Investigators S (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364(13):1195–1206. doi:10.1056/NEJMoa1010494

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffman ML, Wedemeyer H, Berg T, Yoshida EM, Forns X, Lovell SS, Da Silva-Tillmann B, Collins CA, Campbell AL, Podsadecki T, Bernstein B (2014) ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 370(21):1973–1982. doi:10.1056/NEJMoa1402869

    Article  PubMed  CAS  Google Scholar 

  • Rancourt J, Cameron DR, Gorys V, Lamarre D, Poirier M, Thibeault D, Llinas-Brunet M (2004) Peptide-based inhibitors of the hepatitis C virus NS3 protease: structure-activity relationship at the C-terminal position. J Med Chem 47(10):2511–2522. doi:10.1021/jm030573x

    Article  CAS  PubMed  Google Scholar 

  • Rodrigue-Gervais IG, Rigsby H, Jouan L, Sauve D, Sekaly RP, Willems B, Lamarre D (2010) Dendritic cell inhibition is connected to exhaustion of CD8+ T cell polyfunctionality during chronic hepatitis C virus infection. J Immunol 184(6):3134–3144. doi:10.4049/jimmunol.0902522

    Article  CAS  PubMed  Google Scholar 

  • Sanderson PE (1999) Small, noncovalent serine protease inhibitors. Med Res Rev 19(2):179–197

    Article  CAS  PubMed  Google Scholar 

  • Schechter I, Berger A (1967) On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 27(2):157–162

    Article  CAS  PubMed  Google Scholar 

  • Soler M, McHutchison JG, Kwoh TJ, Dorr FA, Pawlotsky JM (2004) Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resistance in the outcome of treatment. Antivir Ther 9(6):953–968

    CAS  PubMed  Google Scholar 

  • Steinkuhler C, Biasiol G, Brunetti M, Urbani A, Koch U, Cortese R, Pessi A, De Francesco R (1998) Product inhibition of the hepatitis C virus NS3 protease. Biochemistry 37(25):8899–8905. doi:10.1021/bi980313v

    Article  CAS  PubMed  Google Scholar 

  • Steinkuhler C, Koch U, Narjes F, Matassa VG (2001) Hepatitis C virus protease inhibitors: current progress and future challenges. Curr Med Chem 8(8):919–932

    Article  CAS  PubMed  Google Scholar 

  • Sudo K, Matsumoto Y, Matsushima M, Fujiwara M, Konno K, Shigeta S, Yokota T (1997a) Novel hepatitis C virus protease inhibitors: thiazolidine derivatives. Biochem Biophys Res Commun 238:643–647

    Article  CAS  PubMed  Google Scholar 

  • Sudo K, Matsumoto Y, Matsushima M, Konno K, Shimotohno K, Shigeta S, Yokota T (1997b) Novel hepatitis C virus protease inhibitors: 2,4,6-trihydroxy, 3-nitro-benzamide derivatives. Antivir Chem Chemother 8:541–544

    CAS  Google Scholar 

  • Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Everson GT, Eley T, Wind-Rotolo M, Huang SP, Gao M, Hernandez D, McPhee F, Sherman D, Hindes R, Symonds W, Pasquinelli C, Grasela DM, Group AIS (2014) Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 370(3):211–221. doi:10.1056/NEJMoa1306218

    Article  CAS  PubMed  Google Scholar 

  • Sulkowski MS, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, Kugelmas M, Murillo A, Weis N, Nahass R, Shibolet O, Serfaty L, Bourliere M, DeJesus E, Zuckerman E, Dutko F, Shaughnessy M, Hwang P, Howe AY, Wahl J, Robertson M, Barr E, Haber B (2015) Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 385(9973):1087–1097. doi:10.1016/S0140-6736(14)61793-1

    Article  CAS  PubMed  Google Scholar 

  • Summa V, Ludmerer SW, McCauley JA, Fandozzi C, Burlein C, Claudio G, Coleman PJ, Dimuzio JM, Ferrara M, Di Filippo M, Gates AT, Graham DJ, Harper S, Hazuda DJ, Huang Q, McHale C, Monteagudo E, Pucci V, Rowley M, Rudd MT, Soriano A, Stahlhut MW, Vacca JP, Olsen DB, Liverton NJ, Carroll SS (2012) MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother 56(8):4161–4167. doi:10.1128/AAC.00324-12

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tomei L, Failla C, Santolini E, De Francesco R, La Monica N (1993) NS3 is a serine protease required for processing of hepatitis C virus polyprotein. J Virol 67(7):4017–4026

    CAS  PubMed  PubMed Central  Google Scholar 

  • Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm BA (2006) Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 70(2):28–38. doi:10.1016/j.antiviral.2005.12.003

    Article  CAS  PubMed  Google Scholar 

  • Tsantrizos YS, Bolger G, Bonneau P, Cameron DR, Goudreau N, Kukolj G, LaPlante SR, Llinas-Brunet M, Nar H, Lamarre D (2003) Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection. Angew Chem 42(12):1356–1360. doi:10.1002/anie.200390347

    Article  CAS  Google Scholar 

  • Tsukiyama-Kohara K, Iizuka N, Kohara M, Nomoto A (1992) Internal ribosome entry site within hepatitis C virus RNA. J Virol 66(3):1476–1483

    CAS  PubMed  PubMed Central  Google Scholar 

  • Urbani A, Bianchi E, Narjes F, Tramontano A, De Francesco R, Steinkuhler C, Pessi A (1997) Substrate specificity of the hepatitis C virus serine protease NS3. J Biol Chem 272(14):9204–9209

    Article  CAS  PubMed  Google Scholar 

  • Walker MP, Hong Z (2002) HCV RNA-dependent RNA polymerase as a target for antiviral development. Curr Opin Pharmacol 2(5):534–540

    Article  CAS  PubMed  Google Scholar 

  • Ward RP, Kugelmas M (2005) Using pegylated interferon and ribavirin to treat patients with chronic hepatitis C. Am Fam Physician 72(4):655–662

    PubMed  Google Scholar 

  • Welch PJ, Tritz R, Yei S, Leavitt M, Yu M, Barber J (1996) A potential therapeutic application of hairpin ribozymes: in vitro and in vivo studies of gene therapy for hepatitis C virus infection. Gene Ther 3(11):994–1001

    CAS  PubMed  Google Scholar 

  • Wu CH, Wu GY (1998) Targeted inhibition of hepatitis C virus-directed gene expression in human hepatoma cell lines. Gastroenterology 114(6):1304–1312

    Article  CAS  PubMed  Google Scholar 

  • Yan Y, Li Y, Munshi S, Sardana V, Cole JL, Sardana M, Steinkuehler C, Tomei L, De Francesco R, Kuo LC, Chen Z (1998) Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 A resolution structure in a hexagonal crystal form. Protein Sci: Publ Protein Soc 7(4):837–847. doi:10.1002/pro.5560070402

    Article  CAS  Google Scholar 

  • Yanagi M, Purcell RH, Emerson SU, Bukh J (1997) Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc Natl Acad Sci U S A 94(16):8738–8743

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yao N, Reichert P, Taremi SS, Prosise WW, Weber PC (1999) Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure 7(11):1353–1363

    Article  CAS  PubMed  Google Scholar 

  • Yuan ZH, Kumar U, Thomas HC, Wen YM, Monjardino J (1997) Expression, purification, and partial characterization of HCV RNA polymerase. Biochem Biophys Res Commun 232(1):231–235. doi:10.1006/bbrc.1997.6249

    Article  CAS  PubMed  Google Scholar 

  • Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Weiland O, Reesink HW, Ferenci P, Hezode C, Esteban R, Investigators V (2014) Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 370(21):1993–2001. doi:10.1056/NEJMoa1316145

    Article  PubMed  CAS  Google Scholar 

  • Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, Brown DD, Wan S, DiNubile MJ, Nguyen BY, Robertson MN, Wahl J, Barr E, Butterton JR (2015) Grazoprevir-Elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. doi:10.7326/M15-0785

    PubMed  Google Scholar 

  • Zhang R, Durkin J, Windsor WT, McNemar C, Ramanathan L, Le HV (1997) Probing the substrate specificity of hepatitis C virus NS3 serine protease by using synthetic peptides. J Virol 71(8):6208–6213

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

This work was supported by grants from the Canadian Institutes for Health Research and a PhD scholarship from FRQ-S to NT.

Author information

Authors and Affiliations

  1. Département de Médecine, Université de Montréal, Montréal, QC, Canada

    Nicolas Tremblay, Alex Young Park & Daniel Lamarre Ph.D.

Authors
  1. Nicolas Tremblay
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alex Young Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniel Lamarre Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel Lamarre Ph.D. .

Editor information

Editors and Affiliations

  1. National Institute of Infectious Disease , Tokyo, Japan

    Tatsuo Miyamura

  2. Departments of Medicine and Microbiology, The Univ of N Carolina at Chapel Hill Departments of Medicine and Microbiology, Chapel Hill, North Carolina, USA

    Stanley M. Lemon

  3. Center for Vaccines and Immunity, The Research Institute at Nationwide Children's Hospital , Ohio, USA

    Christopher M. Walker

  4. National Institute of Infectious Disease, Tokyo, Japan

    Takaji Wakita

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Japan

About this chapter

Cite this chapter

Tremblay, N., Park, A.Y., Lamarre, D. (2016). HCV NS3/4A Protease Inhibitors and the Road to Effective Direct-Acting Antiviral Therapies. In: Miyamura, T., Lemon, S., Walker, C., Wakita, T. (eds) Hepatitis C Virus II. Springer, Tokyo. https://doi.org/10.1007/978-4-431-56101-9_10

Download citation

  • DOI: https://doi.org/10.1007/978-4-431-56101-9_10

  • Published:

  • Publisher Name: Springer, Tokyo

  • Print ISBN: 978-4-431-56099-9

  • Online ISBN: 978-4-431-56101-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation